OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations -- Next-generation PI3Kα pan-mutant inhibitor development candidate for HR+ metastatic breast cancer is expected …